Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer

Breast Cancer: Basic and Clinical Research

Review

Guy Jerusalem¹  Laurence Lousberg² 

[1] Liege University, Liege, Belgium.;Medical Oncology, CHU Sart Tilman Liege, Liege, Belgium.;

关键词: breast cancer;    treatment;    everolimus;    safety;    efficacy;    progression-free survival;   

DOI  :  10.4137/BCBCR.S12443

 received in 2016-10-07, accepted in 2016-11-23,  发布年份 2016

来源: Sage Journals

【 摘 要 】

Everolimus combined with exemestane is an important treatment option for patients suffering from estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer (ABC) who have been previously treated with a nonsteroidal aromatase inhibitor (NSAI). After presentation of phase III registration trial BOLERO-2, several phase IIIb trials have been started to evaluate this regimen in a more real-world setting. Here, we review the efficacy and safety data published or presented at selected international meetings. These studies confirmed the outcome observed in the BOLERO-2 trial. Patient acceptance rate is also discussed by focusing on the permanent everolimus discontinuation rate in these trials. Factors influencing the safety profile are also reported, including the impact of age. The optimal sequence of combined therapy approaches associating targeted and endocrine therapy (ET) has yet to be determined as new treatment options such as cyclin-dependent kinase inhibitors become available. However, everolimus–exemestane remains an important treatment option with a major impact on progression-free survival (PFS) and an acceptable safety profile.

【 授权许可】

CC BY-NC   
© 2016 SAGE Publications.

【 图 表 】

Figure 1.